Condition: Limited Stage Small-Cell Lung Cancer · Sponsor: AstraZeneca
This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Beijing, China | Recruiting |
| Research Site | Cangzhou, China | Recruiting |
| Research Site | Dongguan, China | Recruiting |
| Research Site | Fuzhou, China | Recruiting |
| Research Site | Guangzhou, China | Recruiting |
| Research Site | Huzhou, China | Recruiting |
| Research Site | Jinan, China | Recruiting |
| Research Site | Jinan, China | Recruiting |
| Research Site | Nanjing, China | Recruiting |
| Research Site | Nanning, China | Recruiting |
| Research Site | Ningbo, China | Recruiting |
| Research Site | Shanghai, China | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07161388